Subtitle: Explore eosinophilic esophagitis pathology including ≥15 eosinophils/HPF criteria, endoscopic features, differential diagnosis, and treatment. Exam-oriented review for pathology residents.

Author: Pathology MCQ Editorial Team
Category: Gastrointestinal Pathology
Last Updated: March 2026
Read Time: 12 minutes

This is a medical, educational, exam-oriented pathology review focused on diagnosis and histopathology.

At-a-Glance

• Definition: Chronic immune-mediated esophageal disease with ≥15 eosinophils per high-power field (HPF) after excluding secondary causes.
• Key Diagnostic Features: Symptoms of esophageal dysfunction, peak eosinophil count ≥15/HPF, atopic history common.​
• Difficulty Level: Moderate

Table of Contents

1. At-a-Glance
2. Table of Contents
3. What is Eosinophilic Esophagitis Pathology?
4. View the virtual slide
5. Epidemiology and Clinical Presentation
6. Endoscopic Features of EoE
7. Histopathologic Diagnostic Criteria
8. Differential Diagnosis
9. Pathophysiology
10. Treatment Approaches
11. High – yield MCQS
12. Exam Pearl
13. Key Takeaway
14. Ready to Master This Topic?

What is Eosinophilic Esophagitis Pathology?

Eosinophilic esophagitis pathology refers to the characteristic histologic findings in the esophagus driven by Th2-mediated inflammation, featuring dense eosinophilic infiltration. Diagnosis requires symptoms of esophageal dysfunction, ≥15 eosinophils/HPF on biopsy, and exclusion of mimics like GERD. This condition differs from physiologic esophageal eosinophilia, which is sparse and superficial.​

This image depicts comparative esophageal views: normal (left), GERD reflux (middle), and eosinophilic esophagitis pathology with dense inflammation (right). In eosinophilic esophagitis pathology, intraepithelial eosinophils exceed 15/HPF, confirming immune-mediated disease unresponsive to PPIs alone.​​

View the virtual slide

Epidemiology and Clinical Presentation

Eosinophilic esophagitis affects 0.5–1 in 1000 individuals, with incidence of 1/10,000 annually and rising trends. Males predominate (3:1 ratio), especially young males with atopic conditions like asthma, allergic rhinitis, or atopic dermatitis. Symptoms include dysphagia, food impaction, and chest pain; children present with vomiting or failure to thrive.​​​

Endoscopic Features of EoE

Endoscopic findings in eosinophilic esophagitis include rings, furrows, exudates, edema, and strictures (EREFS classification). Sensitivity of these features ranges 15–46%, specificity 90–95%; normal endoscopy occurs in up to 30% of cases. Biopsies from ≥4 quadrants improve yield.​​​

Histopathologic Diagnostic Criteria

Core criteria for eosinophilic esophagitis pathology: peak ≥15 eosinophils/HPF (≈60/mm²), after PPI trial to exclude PPI-REE. Supporting features: eosinophilic microabscesses, surface layering, basal zone hyperplasia, dilated intercellular spaces, lamina propria fibrosis. Robbins describes degranulated eosinophils, epithelial injury, and Th2 cytokines.

Feature	Description	Diagnostic Relevance ​
Peak Eosinophil Density	≥15/HPF in squamous epithelium	Required criterion
Microabscesses	Clusters >4 adjacent eosinophils	Highly specific
Surface Layering	Eosinophils at luminal surface	Common, with sloughing
Basal Hyperplasia	>20% epithelial thickness	Supports chronicity
Lamina Propria Fibrosis	Subepithelial collagen deposition	Indicates remodeling

This image highlights the diagnostic dilemma in esophageal eosinophilia: low-density scatter (left) vs. high peak clusters (right) in eosinophilic esophagitis pathology. Accurate peak counting prevents misdiagnosis as reflux esophagitis.​​

Differential Diagnosis

Distinguish eosinophilic esophagitis pathology from GERD (sparse eosinophils, responds to PPI), achalasia, or infections. PPI-REE resolves post-PPI; Crohn’s lacks esophageal restriction. Clinicopathologic correlation with atopic history favors EoE.​

Pathophysiology

Th2 inflammation recruits eosinophils via IL-5, IL-13; degranulation releases TGF-β inducing fibrosis. Barrier dysfunction allows antigen penetration, perpetuating cycle. Male predominance and atopy link suggests genetic-environmental factors.

Treatment Approaches

First-line: topical corticosteroids (fluticasone/budesonide) achieve histologic remission in 60–80%. Diet elimination (6-food or elemental) targets allergens; PPI for trial. Dilation for strictures; biologics (dupilumab) emerging.

High – yield MCQS

Exam Pearl

Always confirm ≥15 eos/HPF peak after PPI trial and correlate with atopy for eosinophilic esophagitis pathology diagnosis.​​

Key Takeaway

Eosinophilic esophagitis pathology hinges on histologic density ≥15/HPF, Th2 inflammation, and exclusion of mimics for precise clinicopathologic diagnosis.

Watch quick video review

Ready to Master This Topic?